Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 22, 2020

View Archived Issues

A stinging defeat for infections

Researchers develop a new murine model of seizures with Chd8 haploinsufficiency

DUSP6 is implicated in vascular disease and may be a therapeutic target

Abpro completes dosing in phase I trial of ABP-300 for COVID-19

Optimization of selective antagonists of vasopressin V1A receptor derived from triazolobenzazepines

Hyaluronan is present in the alveolar spaces in lungs of patients with fatal COVID-19

SARS-CoV-2 RNA genome can be targeted using small-molecule binders and RIBOTAC degraders

Phase III study of masitinib in severe asthma uncontrolled by ICS meets primary endpoint

Oxeia initiates phase II study of OXE-103 for concussions

Storm Therapeutics patents METTL3 inhibitors

Centauri Therapeutics divulges new antibacterials

Array BioPharma presents new PTPN11 inhibitors

First patient enrolled in MERKLIN 2 trial of domatinostat plus avelumab in MCC

New CDK inhibitors presented by Aurigene Discovery Technologies

Sorrento Therapeutics patents CD38-targeting antibodies

Poseida and TScan collaborate to develop TCR-T cell therapies for treatment of COVID-19

Second part of daratumumab CASSIOPEIA study in multiple myeloma meets primary endpoint

First-in-human injection of [68]Ga-NT-20.3 found to be well-tolerated without AEs

Phase I data presented for RP-L201 in patients with LAD-I

Gene therapy approaches tackle multiple forms of blindness

FDA clears Cyclo to open global phase III trial of Trappsol Cyclo for NPC in U.S.

MAb 5D3-mertansine antibody-drug conjugate shows efficacy in prostate cancer mouse models

Ultimovacs reports 5-year OS data from phase I trial of UV-1 in NSCLC

Nanoform targets initiation of first-in-human trial of nanoformed piroxicam before year-end

Daiichi initiates phase I trial of DS-1055 in advanced or metastatic solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...